Furuyama W - Search Results

1

A platform technology for generating subunit vaccines against diverse viral pathogens.

Young A, Isaacs A, Scott CAP, Modhiran N, McMillan CLD, Cheung STM, Barr J, Marsh G, Thakur N, Bailey D, Li KSM, Luk HKH, Kok KH, Lau SKP, Woo PCY, Furuyama W, Marzi A, Young PR, Chappell KJ, Watterson D. Young A, et al. Among authors: furuyama w. Front Immunol. 2022 Aug 18;13:963023. doi: 10.3389/fimmu.2022.963023. eCollection 2022. Front Immunol. 2022. PMID: 36059532 Free PMC article.

2

Discovery of an antibody for pan-ebolavirus therapy.

Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H, Takada A. Furuyama W, et al. Sci Rep. 2016 Feb 10;6:20514. doi: 10.1038/srep20514. Sci Rep. 2016. PMID: 26861827 Free PMC article.

3

Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection.

Furuyama W, Marzi A, Carmody AB, Maruyama J, Kuroda M, Miyamoto H, Nanbo A, Manzoor R, Yoshida R, Igarashi M, Feldmann H, Takada A. Furuyama W, et al. PLoS Pathog. 2016 Dec 30;12(12):e1006139. doi: 10.1371/journal.ppat.1006139. eCollection 2016 Dec. PLoS Pathog. 2016. PMID: 28036370 Free PMC article.

4

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.

Suder E, Furuyama W, Feldmann H, Marzi A, de Wit E. Suder E, et al. Among authors: furuyama w. Hum Vaccin Immunother. 2018;14(9):2107-2113. doi: 10.1080/21645515.2018.1473698. Epub 2018 Jun 18. Hum Vaccin Immunother. 2018. PMID: 29757706 Free PMC article. Review.

5

Ebola Virus: Pathogenesis and Countermeasure Development.

Furuyama W, Marzi A. Furuyama W, et al. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi: 10.1146/annurev-virology-092818-015708. Annu Rev Virol. 2019. PMID: 31567063 Review.

6

A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades.

Furuyama W, Reynolds P, Haddock E, Meade-White K, Quynh Le M, Kawaoka Y, Feldmann H, Marzi A. Furuyama W, et al. NPJ Vaccines. 2020 Jan 10;5(1):4. doi: 10.1038/s41541-019-0155-z. eCollection 2020. NPJ Vaccines. 2020. PMID: 31934358 Free PMC article.

7

A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection.

Furuyama W, Nanbo A, Maruyama J, Marzi A, Takada A. Furuyama W, et al. PLoS Negl Trop Dis. 2020 Sep 4;14(9):e0008602. doi: 10.1371/journal.pntd.0008602. eCollection 2020 Sep. PLoS Negl Trop Dis. 2020. PMID: 32886656 Free PMC article.

8

A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection.

Isono M, Furuyama W, Kuroda M, Kondoh T, Igarashi M, Kajihara M, Yoshida R, Manzoor R, Okuya K, Miyamoto H, Feldmann H, Marzi A, Sakaitani M, Nanbo A, Takada A. Isono M, et al. Among authors: furuyama w. Antiviral Res. 2020 Nov;183:104932. doi: 10.1016/j.antiviral.2020.104932. Epub 2020 Sep 15. Antiviral Res. 2020. PMID: 32946918 Free PMC article.

9

Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection.

Furuyama W, Marzi A. Furuyama W, et al. Microorganisms. 2020 Oct 6;8(10):1535. doi: 10.3390/microorganisms8101535. Microorganisms. 2020. PMID: 33036194 Free PMC article.

10

[No title available]

[No authors listed] [No authors listed] PMID: 33420066

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page